VERA
insider transactionsVera Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-74.9K
0 buy · 74.9K sell
Net value · 365d
-$3.1M
$0 in · $3.1M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
12
0 buy · 74.9K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
17.1K sh
Own New
-
Grant·A
Director
$0
17.1K sh
Own New
-
Grant·A
Director
$0
17.1K sh
Own New
-
Grant·A
Director
$0
17.1K sh
Own New
-
Grant·A
Director
$0
17.1K sh
Own New
-
Sell·S
Marshall Fordyce KEY
PRESIDENT AND CEO · 10b5-1
$158.8K
4.3K sh · $37.09
Own -2%
-
Sell·S
Marshall Fordyce KEY
PRESIDENT AND CEO · 10b5-1
$521.0K
14.2K sh · $36.64
Own -6%
-
Sell·S
Marshall Fordyce KEY
PRESIDENT AND CEO · 10b5-1
$41.0K
900 sh · $45.51
Own -0%
-
Sell·S
Marshall Fordyce KEY
PRESIDENT AND CEO · 10b5-1
$353.1K
7.9K sh · $44.58
Own -3%
-
Sell·S
Marshall Fordyce KEY
PRESIDENT AND CEO · 10b5-1
$617.0K
14.1K sh · $43.66
Own -5%
-
Grant·A
Director
$0
44.5K sh
Own New
-
Grant·A
Chief Legal Officer
$0
56.9K sh
Own New
-
Grant·A
Chief Legal Officer
$0
42.4K sh
Own New
-
Exercise·M
SVP, FINANCE, CHIEF ACCT OFFCR
$0
10.0K sh
Own +35%
-
Exercise·M
SVP, FINANCE, CHIEF ACCT OFFCR
$39.4K
10.0K sh · $3.94
Own +15%
-
Sell·S
SVP, FINANCE, CHIEF ACCT OFFCR
$130.9K
3.1K sh · $41.98
Own -5%
-
Sell·S
Chief Regulatory Officer
$91.8K
2.2K sh · $41.98
Own -5%
-
Sell·S
Chief Commercial Officer
$66.4K
1.6K sh · $41.98
Own -2%
-
Sell·S
Chief Operating Officer
$108.3K
2.6K sh · $41.98
Own -5%
-
Sell·S
Sean Grant KEY
CHIEF FINANCIAL OFFICER
$207.8K
4.9K sh · $41.98
Own -4%
-
Sell·S
Marshall Fordyce KEY
PRESIDENT AND CEO
$710.6K
16.9K sh · $41.98
Own -6%
-
Sell·S
Chief Medical Officer
$90.3K
2.2K sh · $41.98
Own -4%
-
Grant·A
SVP, FINANCE, CHIEF ACCT OFFCR
$0
20.0K sh
Own New
-
Grant·A
SVP, FINANCE, CHIEF ACCT OFFCR
$0
10.0K sh
Own +17%
-
Grant·A
Chief Regulatory Officer
$0
50.0K sh
Own New
-
Grant·A
Chief Regulatory Officer
$0
25.0K sh
Own +111%
-
Grant·A
Chief Commercial Officer
$0
40.0K sh
Own New
-
Grant·A
Chief Commercial Officer
$0
20.0K sh
Own +44%
-
Grant·A
Chief Operating Officer
$0
40.0K sh
Own New
-
Grant·A
Chief Operating Officer
$0
20.0K sh
Own +71%
-
Grant·A
Sean Grant KEY
CHIEF FINANCIAL OFFICER
$0
50.0K sh
Own New
-
Grant·A
Sean Grant KEY
CHIEF FINANCIAL OFFICER
$0
25.0K sh
Own +27%
-
Grant·A
Marshall Fordyce KEY
PRESIDENT AND CEO
$0
137.5K sh
Own New
-
Grant·A
Marshall Fordyce KEY
PRESIDENT AND CEO
$0
68.8K sh
Own +34%
-
Grant·A
Chief Medical Officer
$0
50.0K sh
Own New
-
Grant·A
Chief Medical Officer
$0
25.0K sh
Own +89%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 21, 2026 | Christy J. Oliger | Grant A | 17.1K | $0 |
| May 21, 2026 | James R Meyers | Grant A | 17.1K | $0 |
| May 21, 2026 | Michael Morrissey | Grant A | 17.1K | $0 |
| May 21, 2026 | Kimball Hall | Grant A | 17.1K | $0 |
| May 21, 2026 | Andrew Cheng | Grant A | 17.1K | $0 |
| May 12, 2026 | Marshall Fordyce KEY 10b5-1 | Sell S | 4.3K | $158.8K |
| May 12, 2026 | Marshall Fordyce KEY 10b5-1 | Sell S | 14.2K | $521.0K |
| Apr 14, 2026 | Marshall Fordyce KEY 10b5-1 | Sell S | 900 | $41.0K |
| Apr 14, 2026 | Marshall Fordyce KEY 10b5-1 | Sell S | 7.9K | $353.1K |
| Apr 14, 2026 | Marshall Fordyce KEY 10b5-1 | Sell S | 14.1K | $617.0K |
| Apr 1, 2026 | Christy J. Oliger | Grant A | 44.5K | $0 |
| Mar 23, 2026 | Jane Wright-Mitchell | Grant A | 56.9K | $0 |
| Mar 23, 2026 | Jane Wright-Mitchell | Grant A | 42.4K | $0 |
| Mar 13, 2026 | Joseph R Young | Exercise M | 10.0K | $0 |
| Mar 13, 2026 | Joseph R Young | Exercise M | 10.0K | $39.4K |
| Feb 23, 2026 | Joseph R Young | Sell S | 3.1K | $130.9K |
| Feb 23, 2026 | William D. Turner | Sell S | 2.2K | $91.8K |
| Feb 23, 2026 | Laurence Matthew Skelton | Sell S | 1.6K | $66.4K |
| Feb 23, 2026 | David Lee Johnson | Sell S | 2.6K | $108.3K |
| Feb 23, 2026 | Sean Grant KEY | Sell S | 4.9K | $207.8K |
| Feb 23, 2026 | Marshall Fordyce KEY | Sell S | 16.9K | $710.6K |
| Feb 23, 2026 | Robert Brenner | Sell S | 2.2K | $90.3K |
| Feb 4, 2026 | Joseph R Young | Grant A | 20.0K | $0 |
| Feb 4, 2026 | Joseph R Young | Grant A | 10.0K | $0 |
| Feb 4, 2026 | William D. Turner | Grant A | 50.0K | $0 |
| Feb 4, 2026 | William D. Turner | Grant A | 25.0K | $0 |
| Feb 4, 2026 | Laurence Matthew Skelton | Grant A | 40.0K | $0 |
| Feb 4, 2026 | Laurence Matthew Skelton | Grant A | 20.0K | $0 |
| Feb 4, 2026 | David Lee Johnson | Grant A | 40.0K | $0 |
| Feb 4, 2026 | David Lee Johnson | Grant A | 20.0K | $0 |
| Feb 4, 2026 | Sean Grant KEY | Grant A | 50.0K | $0 |
| Feb 4, 2026 | Sean Grant KEY | Grant A | 25.0K | $0 |
| Feb 4, 2026 | Marshall Fordyce KEY | Grant A | 137.5K | $0 |
| Feb 4, 2026 | Marshall Fordyce KEY | Grant A | 68.8K | $0 |
| Feb 4, 2026 | Robert Brenner | Grant A | 50.0K | $0 |
| Feb 4, 2026 | Robert Brenner | Grant A | 25.0K | $0 |
About VERA insider trading
This page tracks insider transactions for Vera Therapeutics, Inc. (VERA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.